Vnitr Lek 2010, 56(5):376-381

Evaluation of cardiovascular high risk population in Specialists Ambulance: ESA

J. Žižka1,*, M. Souček2
1 I. interní klinika Fakultní Thomayerovy nemocnice a IPVZ Praha, přednosta doc. MUDr. Štefan Alušík, CSc.
2 II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.

Background:
Arterial hypertension is the most common CV disease in the Czech Republic with estimated prevalence 35% among population aged 25 to 64 years. Although serious public health problem with significant medical and economic consequences the treatment of HT is currently unsatisfactory. Only 18.4% of patients with arterial HT reach goal BP. There are several factors responsible for this fact, among them low compliance of patients, low dosages of antihypertensive drugs used and low usage of the combination of antihypertensive drugs.

Aim:
To obtain following data from the specialists ambulances (internists and cardiologists) regarding hypertensive patients: frequency of high risk hypertensive patients and proportion of patients with hypertension in whom BP is well controlled (target BP reached). Another goal of the study was to obtain data about pharmacological treatment of hypertensive patients.

Method:
National, multicenter, non-interventional, cross sectional, representative sample, one visit study.

Results:
Data of 19,821 patients with primary hypertension visited office-based internists and cardiologists was analysed. The average age was 64 ± 12 years (range 19-99 years), 53% was women. The mean blood pressure of entire population was 138.5 ± 15.1/81.7 ± 9.1 mm Hg. There were high proportion of patients with well controlled blood pressure (BP below 140/90 mm Hg) - 48% of the patients. Among those with diabetes the proportion of well controlled patients was much lower - only 11% of the patients. Regarding other cardiovascular risk factors the most common was hyperlipidaemia - 66% of the patients, following by diabetes and smoking with 29 and 14% of the patients respectively. 8,444 (43%) of the patients suffered from the coronary artery diseases, 2,251 (11%) patients have experienced stroke or TIA and 1,601 (8%) patients had peripheral artery disease. Regarding antihypertensive therapy, only 21% of the population was treated by monotherapy. The most common was the combination of ACE inhibitors plus beta-blockers or triple-combination of ACE inhibitors plus diuretics plus beta-blockers.

Keywords: arterial hypertension; risk factors; cardiovascular disease; pharmacotherapy

Received: February 19, 2010; Accepted: March 16, 2010; Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Žižka J, Souček M. Evaluation of cardiovascular high risk population in Specialists Ambulance: ESA. Vnitr Lek. 2010;56(5):376-381.
Download citation

References

  1. Widimský J Jr., Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Cor Vasa 2008; 50: K5-K22.
  2. Cífková R. Stav kontroly hypertenze v ČR a ve světě. In: Widimský J et al (eds). Hypertenze. Praha: Triton 2008: 563-557.
  3. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
  4. Widimský J, Sachová M, Souček M et al. Vysoká prevalence a špatná kontrola hypertenze v ordinacích praktických lékařů. Vnitř Lék 2005; 51: 1087-1095.
  5. Sharma AM, Wittchen HU, Kirch W et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004; 22: 479-486. Go to original source... Go to PubMed...
  6. Jozífová M, Cífková R, Škodová Z et al. Porovnání léčby hypertenze a rizikového profilu hypertoniků v obecné populaci a na specializovaném pracovišti. Cor Vasa 2003; 45: 533-541.
  7. Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
  8. Dahlöf B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regiment of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Tria-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
  9. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122: 290-300. Go to original source... Go to PubMed...
  10. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvacular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
  11. Yusuf S, Teo KK, Pogue J et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
  12. Widimský J, Souček M, Sachová M et al. Hypertenze a diabetes mellitus v ordinacích praktických lékařů. Cor Vasa 2005; 47: 127-132.
  13. Mancia G, Laurent S, Agabiti-Rosei L et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158. Go to original source... Go to PubMed...
  14. Widimský J. Komentář k přehodnocení evropských doporučení léčby arteriální hypertenze. Cor Vasa 2010; 52: 75-78. Go to original source...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.